文献速递神经肿瘤

经蝶窦腺瘤切除术后生长激素分泌型垂体腺瘤的延迟缓解

Delayed Remission of Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Adenectomy.
PubMed 文献 · World Neurosurg · 2018-11-14

回顾性分析87例肢端肥大症经蝶窦手术患者,51例(58.6%)获长期GH缓解,其中24例为术后即刻延迟缓解(DR)、9例为术后3个月DR,24例DR患者平均10.2个月(范围3-32个月)获缓解;术后3个月GH谷值是长期缓解的最佳预测指标(AUC=0.944)。作者认为对可能DR的患者术后早期不应追加治疗,应延长随访密切观察。

要点

  • 87例中51例(58.6%)获长期GH缓解,24例(27.6%)为术后即刻DR,9例(10.3%)为术后3个月DR。
  • 24例DR患者平均10.2个月(范围3-32个月)获缓解,期间未接受额外术后治疗。
  • 术后3个月GH谷值预测长期缓解AUC=0.944,灵敏度76.5%、特异度97.2%。

核心结论

  • 对可能获得延迟缓解的特定患者群体,术后早期不应追加治疗,延长随访和密切观察有助于判断手术疗效并指导术后治疗。

研究设计与样本

  • 回顾性研究,纳入87例因肢端肥大症接受经蝶窦手术的患者,回顾术前、术后即刻、术后3个月及长期(2.4±1.1年)的人口学、影像学和内分泌学资料。
  • 延迟缓解定义为术后即刻、3个月或之后未获GH缓解,但在长期随访中未接受任何额外术后治疗而获得缓解。

主要发现

  • 51例(58.6%)获长期GH缓解,其中术后即刻DR 24例(27.6%)、术后3个月DR 9例(10.3%)。
  • 24例DR患者平均于10.2个月(范围3-32个月)获缓解。
  • 术后即刻随机GH和口服葡萄糖负荷后GH谷值DR组显著低于未缓解组(分别为2.73±3.17和2.03±2.59 vs. 8.05±10.35和5.55±5.91 μg/L)。
  • 术后3个月GH谷值DR组显著低于未缓解组(1.63±2.82 vs. 3.48±4.25 μg/L,P=0.007)。
  • 术后即刻随机GH可有效预测长期缓解(Spearman ρ=0.513,AUC=0.905>0.90);最佳预测指标为术后3个月GH谷值(Spearman ρ=0.728,AUC=0.944>0.90),灵敏度76.5%、特异度97.2%。

临床怎么用

  • 作者认为,对可能获得延迟缓解的特定患者群体,术后早期不应追加治疗。
  • 作者认为,延长随访和密切观察有助于判断手术疗效并指导术后治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the clinical characteristics of delayed remission (DR) of growth hormone (GH)-secreting pituitary adenoma after transsphenoidal adenectomy and inform follow-up treatments. METHODS: We retrospectively reviewed 87 patients who had undergone transsphenoidal surgery for acromegaly. Demographic, radiological, and endocrinological data were reviewed before, immediately after, 3 months after, and in the long term (2.4 ± 1.1 years) after surgery. The definition of DR was that patients did not achieve GH remission immediately, 3 months, or later after surgery, but did so in the long term without any additional postoperative treatment. RESULTS: Fifty-one patients (58.6%) achieved long-term GH remission. There were 24 (27.6%) DR patients immediately postoperatively and 9 (10.3%) DR patients 3 months postoperatively. On average, the 24 DR patients achieved remission at 10.2 (range, 3-32) months. Immediate postoperative random and nadir GH after an oral glucose load were significantly lower in the DR group than in the nonremission group (2.73 ± 3.17 and 2.03 ± 2.59 vs. 8.05 ± 10.35 and 5.55 ± 5.91 μg/L, respectively). Three-month postoperative nadir GH was significantly lower in the DR group than in the nonremission group (1.63 ± 2.82 vs. 3.48 ± 4.25 μg/L, P = 0.007). Immediate postoperative random GH effectively predicted long-term remission (Spearman's ρ = 0.513, area under the curve = 0.905 > 0.90). However, the best predictor of long-term remission was 3-month postoperative nadir GH (Spearman's ρ = 0.728, area under the curve = 0.944 > 0.90), with 76.5% sensitivity and 97.2% specificity. CONCLUSIONS: For certain groups of patients likely to achieve DR, additional treatments should not be performed early after surgery. Prolonged follow-up and close observation could help determine the therapeutic effect of surgery and guide postoperative treatments.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wang Z, Guo X, Gao L, et al. Delayed Remission of Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Adenectomy. World Neurosurg. 2018. PMID: 30447463. doi:10.1016/j.wneu.2018.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。